Skip to content
The Policy VaultThe Policy Vault

gabapentin immediate-release (capsules, tablets, oral solution)CareFirst (Caremark)

Management of postherpetic neuralgia in adults

Initial criteria

  • Authorization may be granted when the patient is NOT taking more than 3600 mg per day of gabapentin.

Approval duration

12 months